| Trade Date |
Insider |
Title |
Buy or Sell |
Quantity |
Security Type |
Price |
Proceeds |
Transaction Conviction |
Position Quantity |
Position Value |
Positon Conviction |
SEC Link |
Nature of Ownership |
2020-06-16 | Robert Lorne Hopfner | - | Buy | 93,000 | Common Stock | $16.00 | -$1,488,000.00 | - | 2,222,967 | $35,567,472.00 | - | Form 4 | By Pivotal bioVenture Partners Fund I, L.P. | 2020-06-16 | Robert Lorne Hopfner | - | Buy | 211,237 | Common Stock | $0.00 | $0.00 | - | 2,129,967 | $0.00 | - | Form 4 | By Pivotal bioVenture Partners Fund I, L.P. | 2020-06-16 | Robert Lorne Hopfner | - | Buy | 226,236 | Common Stock | $0.00 | $0.00 | - | 1,918,730 | $0.00 | - | Form 4 | By Pivotal bioVenture Partners Fund I, L.P. | 2020-06-16 | Robert Lorne Hopfner | - | Buy | 1,692,494 | Common Stock | $0.00 | $0.00 | - | 1,692,494 | $0.00 | - | Form 4 | By Pivotal bioVenture Partners Fund I, L.P. | 2020-06-16 | Patrick J Heron | - | Buy | 250,000 | Common Stock | $16.00 | -$4,000,000.00 | 51.67 [ Very High ] | 2,309,554 | $36,952,864.00 | 477.32 [Very High] | Form 4 | By Frazier Life Sciences VIII, L.P. | 2020-06-16 | Patrick J Heron | - | Buy | 140,824 | Common Stock | $0.00 | $0.00 | - | 2,059,554 | $0.00 | 425.65 [Very High] | Form 4 | By Frazier Life Sciences VIII, L.P. | 2020-06-16 | Patrick J Heron | - | Buy | 226,236 | Common Stock | $0.00 | $0.00 | - | 1,918,730 | $0.00 | 396.55 [Very High] | Form 4 | By Frazier Life Sciences VIII, L.P. | 2020-06-16 | Patrick J Heron | - | Buy | 1,692,494 | Common Stock | $0.00 | $0.00 | - | 1,692,494 | $0.00 | 349.79 [Very High] | Form 4 | By Frazier Life Sciences VIII, L.P. | 2020-06-16 | Tpg Group Holdings (sbs) Advisors, Inc. | - | Buy | 4,219,053 | Common Stock | $0.00 | $0.00 | - | 4,219,053 | $0.00 | - | Form 4 | See Explanation of Responses | 2020-06-16 | Tpg Group Holdings (sbs) Advisors, Inc. | - | Buy | 937,500 | Common Stock | $16.00 | -$15,000,000.00 | - | 5,156,553 | $82,504,848.00 | - | Form 4 | See Explanation of Responses | 2020-06-16 | Kurt Von Emster | - | Buy | 2,185,415 | Common Stock, $0.001 par value per share | $0.00 | $0.00 | - | 2,185,415 | $0.00 | - | Form 4 | See Footnotes | 2020-06-16 | Kurt Von Emster | - | Buy | 1,217,074 | Common Stock, $0.001 par value per share | $0.00 | $0.00 | - | 3,402,489 | $0.00 | - | Form 4 | See Footnotes | 2020-06-16 | Kurt Von Emster | - | Buy | 454,812 | Common Stock, $0.001 par value per share | $0.00 | $0.00 | - | 3,857,301 | $0.00 | - | Form 4 | See Footnotes | 2020-06-16 | Kurt Von Emster | - | Buy | 298,917 | Common Stock, $0.001 par value per share | $0.00 | $0.00 | - | 4,156,218 | $0.00 | - | Form 4 | See Footnotes | 2020-06-16 | Kurt Von Emster | - | Buy | 12,500 | Common Stock, $0.001 par value per share | $16.00 | -$200,000.00 | - | 4,168,718 | $66,699,488.00 | - | Form 4 | See Footnotes | 2020-09-29 | Ra Capital Management, L.p. | - | Sell | 80,707 | Common Stock | $52.08 | $4,203,220.56 | 15.85 [ Very High ] | 5,408,474 | $281,673,325.92 | 1,062.07 [Very High] | Form 4 | See Footnote | 2020-09-30 | Ra Capital Management, L.p. | - | Sell | 124,656 | Common Stock | $50.27 | $6,266,457.12 | 24.48 [ Very High ] | 5,283,818 | $265,617,530.86 | 1,037.59 [Very High] | Form 4 | See Footnote | 2020-10-07 | Ra Capital Management, L.p. | - | Sell | 98,597 | Common Stock | $50.95 | $5,023,517.15 | 19.36 [ Very High ] | 5,169,254 | $263,373,491.30 | 1,015.09 [Very High] | Form 4 | See Footnote | 2020-10-08 | Ra Capital Management, L.p. | - | Sell | 167,661 | Common Stock | $50.69 | $8,498,736.09 | 32.92 [ Very High ] | 5,001,593 | $253,530,749.17 | 982.17 [Very High] | Form 4 | See Footnote | 2020-12-09 | William J Newell | - | Buy | 22,228 | Common Stock | $1.29 | -$28,674.12 | 4.36 [ Very High ] | 66,684 | $86,022.36 | 13.09 [Average] | Form 4 | - | 2020-12-15 | Tpg Group Holdings (sbs) Advisors, Inc. | - | Sell | 6,276 | Common Stock | $33.02 | $207,233.52 | 1.23 [ High ] | 5,150,277 | $170,062,146.54 | 1,010.85 [Very High] | Form 4 | See Explanation of Responses | 2020-12-15 | Tpg Group Holdings (sbs) Advisors, Inc. | - | Sell | 75,703 | Common Stock | $32.46 | $2,457,319.38 | 14.86 [ Very High ] | 5,074,574 | $164,720,672.04 | 995.99 [Very High] | Form 4 | See Explanation of Responses | 2020-12-21 | Grant Pickering | President & CEO | Buy | 15,000 | Common Stock | $1.79 | -$26,850.00 | 2.94 [ Very High ] | 588,191 | $1,052,861.89 | 115.44 [Very High] | Form 4 | - | 2020-12-21 | Grant Pickering | President & CEO | Sell | 7,196 | Common Stock | $28.42 | $204,510.32 | 1.41 [ High ] | 580,995 | $16,511,877.90 | 114.03 [Very High] | Form 4 | - | 2020-12-21 | Grant Pickering | President & CEO | Sell | 5,691 | Common Stock | $29.08 | $165,494.28 | 1.12 [ High ] | 575,304 | $16,729,840.32 | 112.92 [Very High] | Form 4 | - | 2020-12-21 | Grant Pickering | President & CEO | Sell | 2,113 | Common Stock | $29.88 | $63,136.44 | 0.41 [ Average ] | 573,191 | $17,126,947.08 | 112.50 [Very High] | Form 4 | - | 2020-12-28 | Grant Pickering | President & CEO | Buy | 5,500 | Common Stock | $1.79 | -$9,845.00 | 1.08 [ High ] | 578,691 | $1,035,856.89 | 113.58 [Very High] | Form 4 | - | 2020-12-29 | Jeff Fairman | VP, Research | Buy | 740 | Common Stock | $1.79 | -$1,324.60 | 0.15 [ Low ] | 1,408 | $2,520.32 | 0.28 [Very Low] | Form 4 | - | 2021-01-06 | Robert Lorne Hopfner | - | Sell | 34,913 | Common Stock | $29.24 | $1,020,856.12 | 6.85 [ Very High ] | 2,188,054 | $63,978,698.96 | 429.45 [Very High] | Form 4 | By Pivotal bioVenture Partners Fund I, L.P. | 2021-01-06 | Robert Lorne Hopfner | - | Sell | 22,507 | Common Stock | $29.99 | $674,984.93 | 4.42 [ Very High ] | 2,165,547 | $64,944,754.53 | 425.03 [Very High] | Form 4 | By Pivotal bioVenture Partners Fund I, L.P. | 2021-01-07 | Robert Lorne Hopfner | - | Sell | 24,524 | Common Stock | $27.75 | $680,541.00 | 4.81 [ Very High ] | 2,141,023 | $59,413,388.25 | 420.22 [Very High] | Form 4 | By Pivotal bioVenture Partners Fund I, L.P. | 2021-01-07 | Robert Lorne Hopfner | - | Sell | 22,587 | Common Stock | $28.80 | $650,505.60 | 4.43 [ Very High ] | 2,118,436 | $61,010,956.80 | 415.79 [Very High] | Form 4 | By Pivotal bioVenture Partners Fund I, L.P. | 2021-01-07 | Robert Lorne Hopfner | - | Sell | 469 | Common Stock | $29.51 | $13,840.19 | 0.09 [ Very Low ] | 2,117,967 | $62,501,206.17 | 415.70 [Very High] | Form 4 | By Pivotal bioVenture Partners Fund I, L.P. | 2021-01-08 | Robert Lorne Hopfner | - | Sell | 31,468 | Common Stock | $26.43 | $831,699.24 | 6.18 [ Very High ] | 2,086,499 | $55,146,168.57 | 409.52 [Very High] | Form 4 | By Pivotal bioVenture Partners Fund I, L.P. | 2021-01-08 | Robert Lorne Hopfner | - | Sell | 8,944 | Common Stock | $27.08 | $242,203.52 | 1.76 [ High ] | 2,077,555 | $56,260,189.40 | 407.76 [Very High] | Form 4 | By Pivotal bioVenture Partners Fund I, L.P. | 2021-01-08 | Robert Lorne Hopfner | - | Sell | 200 | Common Stock | $28.23 | $5,646.00 | 0.04 [ Very Low ] | 2,077,355 | $58,643,731.65 | 407.72 [Very High] | Form 4 | By Pivotal bioVenture Partners Fund I, L.P. | 2021-01-11 | Paul Sauer | SVP Process Dev, Manufacturing | Buy | 2,500 | Common Stock | $1.79 | -$4,475.00 | 0.49 [ Average ] | 80,399 | $143,914.21 | 15.78 [Average] | Form 4 | - | 2021-01-11 | Paul Sauer | SVP Process Dev, Manufacturing | Sell | 973 | Common Stock | $25.38 | $24,694.74 | 0.19 [ Low ] | 79,426 | $2,015,831.88 | 15.59 [Average] | Form 4 | - | 2021-01-11 | Paul Sauer | SVP Process Dev, Manufacturing | Sell | 1,527 | Common Stock | $26.74 | $40,831.98 | 0.30 [ Average ] | 77,899 | $2,083,019.26 | 15.29 [Average] | Form 4 | - | 2021-01-11 | Robert Lorne Hopfner | - | Sell | 12,480 | Common Stock | $25.42 | $317,241.60 | 2.45 [ High ] | 2,064,875 | $52,489,122.50 | 405.27 [Very High] | Form 4 | By Pivotal bioVenture Partners Fund I, L.P. | 2021-01-11 | Robert Lorne Hopfner | - | Sell | 24,980 | Common Stock | $26.69 | $666,716.20 | 4.90 [ Very High ] | 2,039,895 | $54,444,797.55 | 400.37 [Very High] | Form 4 | By Pivotal bioVenture Partners Fund I, L.P. | 2021-01-11 | Robert Lorne Hopfner | - | Sell | 12,206 | Common Stock | $27.02 | $329,806.12 | 2.40 [ High ] | 2,027,689 | $54,788,156.78 | 397.98 [Very High] | Form 4 | By Pivotal bioVenture Partners Fund I, L.P. | 2021-01-12 | Robert Lorne Hopfner | - | Sell | 17,666 | Common Stock | $26.35 | $465,499.10 | 3.47 [ Very High ] | 2,010,023 | $52,964,106.05 | 394.51 [Very High] | Form 4 | By Pivotal bioVenture Partners Fund I, L.P. | 2021-01-12 | Robert Lorne Hopfner | - | Sell | 901 | Common Stock | $27.05 | $24,372.05 | 0.18 [ Low ] | 2,009,122 | $54,346,750.10 | 394.33 [Very High] | Form 4 | By Pivotal bioVenture Partners Fund I, L.P. | 2021-01-13 | Robert Lorne Hopfner | - | Sell | 26,010 | Common Stock | $25.90 | $673,659.00 | 5.11 [ Very High ] | 1,983,112 | $51,362,600.80 | 389.23 [Very High] | Form 4 | By Pivotal bioVenture Partners Fund I, L.P. | 2021-01-13 | Robert Lorne Hopfner | - | Sell | 3,100 | Common Stock | $26.34 | $81,654.00 | 0.61 [ Average ] | 1,980,012 | $52,153,516.08 | 388.62 [Very High] | Form 4 | By Pivotal bioVenture Partners Fund I, L.P. | 2021-01-14 | Robert Lorne Hopfner | - | Sell | 14,918 | Common Stock | $25.88 | $386,077.84 | 2.93 [ Very High ] | 1,965,094 | $50,856,632.72 | 385.69 [Very High] | Form 4 | By Pivotal bioVenture Partners Fund I, L.P. | 2021-01-15 | Robert Lorne Hopfner | - | Sell | 22,869 | Common Stock | $25.74 | $588,648.06 | 4.49 [ Very High ] | 1,942,225 | $49,992,871.50 | 381.20 [Very High] | Form 4 | By Pivotal bioVenture Partners Fund I, L.P. | 2021-01-15 | Robert Lorne Hopfner | - | Sell | 3,808 | Common Stock | $26.05 | $99,198.40 | 0.75 [ Average ] | 1,938,417 | $50,495,762.85 | 380.45 [Very High] | Form 4 | By Pivotal bioVenture Partners Fund I, L.P. | 2021-01-19 | Robert Lorne Hopfner | - | Sell | 42,516 | Common Stock | $25.55 | $1,086,283.80 | 8.34 [ Very High ] | 1,895,901 | $48,440,270.55 | 372.11 [Very High] | Form 4 | By Pivotal bioVenture Partners Fund I, L.P. | 2021-01-19 | Robert Lorne Hopfner | - | Sell | 7,000 | Common Stock | $26.05 | $182,350.00 | 1.37 [ High ] | 1,888,901 | $49,205,871.05 | 370.74 [Very High] | Form 4 | By Pivotal bioVenture Partners Fund I, L.P. | 2021-01-15 | Jane Wright-mitchell | General Counsel | Buy | 2,500 | Common Stock | $2.03 | -$5,075.00 | 0.49 [ Average ] | 4,062 | $8,245.86 | 0.80 [Very Low] | Form 4 | - | 2021-01-15 | Jane Wright-mitchell | General Counsel | Sell | 2,500 | Common Stock | $26.00 | $65,000.00 | 0.49 [ Average ] | 1,562 | $40,612.00 | 0.31 [Very Low] | Form 4 | - | 2021-01-19 | Grant Pickering | President & CEO | Buy | 15,000 | Common Stock | $1.79 | -$26,850.00 | 2.94 [ Very High ] | 593,691 | $1,062,706.89 | 116.52 [Very High] | Form 4 | - | 2021-01-19 | Grant Pickering | President & CEO | Sell | 13,433 | Common Stock | $25.01 | $335,959.33 | 2.64 [ Very High ] | 580,258 | $14,512,252.58 | 113.89 [Very High] | Form 4 | - | 2021-01-19 | Grant Pickering | President & CEO | Sell | 1,567 | Common Stock | $25.87 | $40,538.29 | 0.31 [ Average ] | 578,691 | $14,970,736.17 | 113.58 [Very High] | Form 4 | - | 2021-01-20 | Jim Wassil | Chief Operating Officer | Buy | 3,000 | Common Stock | $2.42 | -$7,260.00 | 0.59 [ Average ] | 19,381 | $46,902.02 | 3.80 [Low] | Form 4 | - | 2021-01-20 | Jim Wassil | Chief Operating Officer | Sell | 3,000 | Common Stock | $25.50 | $76,500.00 | 0.59 [ Average ] | 16,381 | $417,715.50 | 3.22 [Low] | Form 4 | - | 2021-01-20 | Robert Lorne Hopfner | - | Sell | 19,046 | Common Stock | $25.35 | $482,816.10 | 3.74 [ Very High ] | 1,869,855 | $47,400,824.25 | 367.00 [Very High] | Form 4 | By Pivotal bioVenture Partners Fund I, L.P. | 2021-01-21 | Robert Lorne Hopfner | - | Sell | 100 | Common Stock | $25.11 | $2,511.00 | 0.02 [ Very Low ] | 1,869,755 | $46,949,548.05 | 366.98 [Very High] | Form 4 | By Pivotal bioVenture Partners Fund I, L.P. | 2021-01-22 | Robert Lorne Hopfner | - | Sell | 11,383 | Common Stock | $25.16 | $286,396.28 | 2.23 [ High ] | 1,858,372 | $46,756,639.52 | 364.74 [Very High] | Form 4 | By Pivotal bioVenture Partners Fund I, L.P. | 2021-01-25 | Robert Lorne Hopfner | - | Sell | 19,511 | Common Stock | $25.61 | $499,676.71 | 3.83 [ Very High ] | 1,838,861 | $47,093,230.21 | 360.91 [Very High] | Form 4 | By Pivotal bioVenture Partners Fund I, L.P. | 2021-01-25 | Robert Lorne Hopfner | - | Sell | 15,461 | Common Stock | $26.07 | $403,068.27 | 3.03 [ Very High ] | 1,823,400 | $47,536,038.00 | 357.88 [Very High] | Form 4 | By Pivotal bioVenture Partners Fund I, L.P. | 2021-01-26 | Robert Lorne Hopfner | - | Sell | 16,769 | Common Stock | $25.23 | $423,081.87 | 3.29 [ Very High ] | 1,806,631 | $45,581,300.13 | 354.59 [Very High] | Form 4 | By Pivotal bioVenture Partners Fund I, L.P. | 2021-01-26 | Robert Lorne Hopfner | - | Sell | 1,373 | Common Stock | $26.13 | $35,876.49 | 0.27 [ Low ] | 1,805,258 | $47,171,391.54 | 354.32 [Very High] | Form 4 | By Pivotal bioVenture Partners Fund I, L.P. | 2021-01-27 | Robert Lorne Hopfner | - | Sell | 2,140 | Common Stock | $25.30 | $54,142.00 | 0.42 [ Average ] | 1,803,118 | $45,618,885.40 | 353.90 [Very High] | Form 4 | By Pivotal bioVenture Partners Fund I, L.P. | 2021-01-26 | Jeff Fairman | VP, Research | Buy | 4,750 | Common Stock | $0.04 | -$190.00 | 0.93 [ High ] | 6,158 | $246.32 | 1.21 [Very Low] | Form 4 | - | 2021-01-26 | Jeff Fairman | VP, Research | Sell | 4,325 | Common Stock | $25.20 | $108,990.00 | 0.85 [ High ] | 1,833 | $46,191.60 | 0.36 [Very Low] | Form 4 | - | 2021-01-26 | Jeff Fairman | VP, Research | Sell | 425 | Common Stock | $25.94 | $11,024.50 | 0.08 [ Very Low ] | 1,408 | $36,523.52 | 0.28 [Very Low] | Form 4 | - | 2021-01-28 | Robert Lorne Hopfner | - | Sell | 2,000 | Common Stock | $25.07 | $50,140.00 | 0.39 [ Average ] | 1,801,118 | $45,154,028.26 | 353.51 [Very High] | Form 4 | By Pivotal bioVenture Partners Fund I, L.P. | 2021-02-02 | Robert Lorne Hopfner | - | Sell | 14,234 | Common Stock | $25.13 | $357,700.42 | 2.79 [ Very High ] | 1,786,884 | $44,904,394.92 | 350.71 [Very High] | Form 4 | By Pivotal bioVenture Partners Fund I, L.P. | 2021-02-03 | Robert Lorne Hopfner | - | Sell | 2,768 | Common Stock | $25.06 | $69,366.08 | 0.54 [ Average ] | 1,784,116 | $44,709,946.96 | 350.17 [Very High] | Form 4 | By Pivotal bioVenture Partners Fund I, L.P. | 2021-02-08 | Robert Lorne Hopfner | - | Sell | 50,874 | Common Stock | $25.64 | $1,304,409.36 | 9.99 [ Very High ] | 1,733,242 | $44,440,324.88 | 340.18 [Very High] | Form 4 | By Pivotal bioVenture Partners Fund I, L.P. | 2021-02-08 | Robert Lorne Hopfner | - | Sell | 28,922 | Common Stock | $26.06 | $753,707.32 | 5.68 [ Very High ] | 1,704,320 | $44,414,579.20 | 334.51 [Very High] | Form 4 | By Pivotal bioVenture Partners Fund I, L.P. | 2021-02-09 | Robert Lorne Hopfner | - | Sell | 38,248 | Common Stock | $27.12 | $1,037,285.76 | 7.51 [ Very High ] | 1,666,072 | $45,183,872.64 | 327.00 [Very High] | Form 4 | By Pivotal bioVenture Partners Fund I, L.P. | 2021-02-09 | Robert Lorne Hopfner | - | Sell | 88,756 | Common Stock | $28.07 | $2,491,380.92 | 17.42 [ Very High ] | 1,577,316 | $44,275,260.12 | 309.58 [Very High] | Form 4 | By Pivotal bioVenture Partners Fund I, L.P. | 2021-02-09 | Robert Lorne Hopfner | - | Sell | 93,740 | Common Stock | $28.75 | $2,695,025.00 | 18.40 [ Very High ] | 1,483,576 | $42,652,810.00 | 291.18 [Very High] | Form 4 | By Pivotal bioVenture Partners Fund I, L.P. | 2021-02-10 | Robert Lorne Hopfner | - | Sell | 37,271 | Common Stock | $25.75 | $959,728.25 | 7.32 [ Very High ] | 1,446,305 | $37,242,353.75 | 283.87 [Very High] | Form 4 | By Pivotal bioVenture Partners Fund I, L.P. | 2021-02-10 | Robert Lorne Hopfner | - | Sell | 26,688 | Common Stock | $26.78 | $714,704.64 | 5.24 [ Very High ] | 1,419,617 | $38,017,343.26 | 278.63 [Very High] | Form 4 | By Pivotal bioVenture Partners Fund I, L.P. | 2021-02-10 | Robert Lorne Hopfner | - | Sell | 7,567 | Common Stock | $27.64 | $209,151.88 | 1.49 [ High ] | 1,412,050 | $39,029,062.00 | 277.14 [Very High] | Form 4 | By Pivotal bioVenture Partners Fund I, L.P. | 2021-02-10 | Robert Lorne Hopfner | - | Sell | 6,632 | Common Stock | $28.66 | $190,073.12 | 1.30 [ High ] | 1,405,418 | $40,279,279.88 | 275.84 [Very High] | Form 4 | By Pivotal bioVenture Partners Fund I, L.P. | 2021-02-11 | Paul Sauer | SVP Process Dev, Manufacturing | Buy | 2,500 | Common Stock | $1.79 | -$4,475.00 | 0.49 [ Average ] | 80,399 | $143,914.21 | 15.78 [High] | Form 4 | - | 2021-02-11 | Paul Sauer | SVP Process Dev, Manufacturing | Sell | 2,184 | Common Stock | $26.56 | $58,007.04 | 0.43 [ Average ] | 78,215 | $2,077,390.40 | 15.35 [Average] | Form 4 | - | 2021-02-11 | Paul Sauer | SVP Process Dev, Manufacturing | Sell | 316 | Common Stock | $27.27 | $8,617.32 | 0.06 [ Very Low ] | 77,899 | $2,124,305.73 | 15.29 [Average] | Form 4 | - | 2021-02-16 | Jane Wright-mitchell | General Counsel | Buy | 2,500 | Common Stock | $2.03 | -$5,075.00 | 0.49 [ Average ] | 4,062 | $8,245.86 | 0.80 [Very Low] | Form 4 | - | 2021-02-16 | Jane Wright-mitchell | General Counsel | Sell | 2,500 | Common Stock | $26.95 | $67,375.00 | 0.49 [ Average ] | 1,562 | $42,095.90 | 0.31 [Very Low] | Form 4 | - | 2021-02-22 | Grant Pickering | President & CEO | Buy | 15,000 | Common Stock | $1.79 | -$26,850.00 | 2.94 [ Very High ] | 593,691 | $1,062,706.89 | 116.52 [Very High] | Form 4 | - | 2021-02-22 | Grant Pickering | President & CEO | Sell | 8,364 | Common Stock | $26.27 | $219,722.28 | 1.64 [ High ] | 585,327 | $15,376,540.29 | 114.88 [Very High] | Form 4 | - | 2021-02-22 | Grant Pickering | President & CEO | Sell | 6,636 | Common Stock | $26.72 | $177,313.92 | 1.30 [ High ] | 578,691 | $15,462,623.52 | 113.58 [Very High] | Form 4 | - | 2021-02-22 | Jim Wassil | Chief Operating Officer | Buy | 3,000 | Common Stock | $2.42 | -$7,260.00 | 0.59 [ Average ] | 19,381 | $46,902.02 | 3.80 [Low] | Form 4 | - | 2021-02-22 | Jim Wassil | Chief Operating Officer | Sell | 1,199 | Common Stock | $26.43 | $31,689.57 | 0.24 [ Low ] | 18,182 | $480,550.26 | 3.57 [Low] | Form 4 | - | 2021-02-22 | Jim Wassil | Chief Operating Officer | Sell | 1,801 | Common Stock | $26.99 | $48,608.99 | 0.35 [ Average ] | 16,381 | $442,123.19 | 3.22 [Low] | Form 4 | - | 2021-02-26 | Jeff Fairman | VP, Research | Buy | 4,750 | Common Stock | $0.04 | -$190.00 | 0.93 [ High ] | 6,158 | $246.32 | 1.21 [Very Low] | Form 4 | - | 2021-02-26 | Jeff Fairman | VP, Research | Sell | 3,310 | Common Stock | $23.73 | $78,546.30 | 0.65 [ Average ] | 2,848 | $67,583.04 | 0.56 [Very Low] | Form 4 | - | 2021-02-26 | Jeff Fairman | VP, Research | Sell | 1,372 | Common Stock | $24.34 | $33,394.48 | 0.27 [ Low ] | 1,476 | $35,925.84 | 0.29 [Very Low] | Form 4 | - | 2021-02-26 | Jeff Fairman | VP, Research | Sell | 68 | Common Stock | $25.33 | $1,722.44 | - | 1,408 | $35,664.64 | 0.28 [Very Low] | Form 4 | - | 2021-03-11 | Paul Sauer | SVP Process Dev, Manufacturing | Buy | 2,500 | Common Stock | $1.79 | -$4,475.00 | 0.49 [ Average ] | 80,399 | $143,914.21 | 15.78 [High] | Form 4 | - | 2021-03-11 | Paul Sauer | SVP Process Dev, Manufacturing | Sell | 2,500 | Common Stock | $25.00 | $62,500.00 | 0.49 [ Average ] | 77,899 | $1,947,475.00 | 15.29 [High] | Form 4 | - | 2021-03-15 | Jane Wright-mitchell | General Counsel | Buy | 2,500 | Common Stock | $2.03 | -$5,075.00 | 0.49 [ Average ] | 4,062 | $8,245.86 | 0.80 [Very Low] | Form 4 | - | 2021-03-15 | Jane Wright-mitchell | General Counsel | Sell | 1,013 | Common Stock | $27.01 | $27,361.13 | 0.20 [ Low ] | 3,049 | $82,353.49 | 0.60 [Very Low] | Form 4 | - | 2021-03-15 | Jane Wright-mitchell | General Counsel | Sell | 1,487 | Common Stock | $27.49 | $40,877.63 | 0.29 [ Average ] | 1,562 | $42,939.38 | 0.31 [Very Low] | Form 4 | - | 2021-03-19 | Grant Pickering | President & CEO | Buy | 15,000 | Common Stock | $1.79 | -$26,850.00 | 2.94 [ Very High ] | 593,691 | $1,062,706.89 | 116.52 [Very High] | Form 4 | - | 2021-03-19 | Grant Pickering | President & CEO | Sell | 15,000 | Common Stock | $25.77 | $386,550.00 | 2.94 [ Very High ] | 578,691 | $14,912,867.07 | 113.58 [Very High] | Form 4 | - | 2021-03-26 | Jeff Fairman | VP, Research | Buy | 4,750 | Common Stock | $0.04 | -$190.00 | 0.93 [ High ] | 6,158 | $246.32 | 1.21 [Very Low] | Form 4 | - | 2021-03-26 | Jeff Fairman | VP, Research | Sell | 3,389 | Common Stock | $23.64 | $80,115.96 | 0.67 [ Average ] | 2,769 | $65,459.16 | 0.54 [Very Low] | Form 4 | - | 2021-03-26 | Jeff Fairman | VP, Research | Sell | 1,361 | Common Stock | $24.48 | $33,317.28 | 0.27 [ Low ] | 1,408 | $34,467.84 | 0.28 [Very Low] | Form 4 | - | 2021-04-05 | Paul Sauer | SVP Process Dev, Manufacturing | Sell | 38,308 | Common Stock | $0.00 | $0.00 | - | 39,591 | $0.00 | 7.77 [Average] | Form 4 | - |
